Please login to the form below

Not currently logged in
Email:
Password:

TiGenix

This page shows the latest TiGenix news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Alofisel, which works by a local administration of allogeneic expanded adipose-derived stem cells (eASCs), was initially manufactured at Belgian biopharma TiGenix, which entered into a licensing agreement with Takeda. ... TiGenix has another

Latest news

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    Takeda offers 520m for stem cell firm TiGenix. The deal will go ahead if the Japanese pharma company can secure an 85% stake in the biotech. ... Takeda has launched a takeover bid for Belgian biotech TiGenix, which has completed late-stage testing of a

  • CHMP backs Europe’s first allogeneic stem cell therapy CHMP backs Europe’s first allogeneic stem cell therapy

    CHMP backs Europe’ s first allogeneic stem cell therapy. Takeda has ex-US rights to the Crohn's disease treatment from biotech TiGenix. ... TiGenix still owns the US rights to Cx601, considered a larger market opportunity for the therapy than Europe.

  • TiGenix’s Crohn's fistulas treatment wins orphan drug status TiGenix’s Crohn's fistulas treatment wins orphan drug status

    TiGenix’ s Crohn's fistulas treatment wins orphan drug status. FDA designation follows positive trial results. ... Meanwhile, TiGenix and partner Takeda has said it will explore expedited pathways to accelerate the submission and review process for US

  • TiGenix cell therapy for Crohn's fistulas shows long-term benefit TiGenix cell therapy for Crohn's fistulas shows long-term benefit

    TiGenix cell therapy for Crohn's fistulas shows long-term benefit. Phase III data for the Takeda-partnered drug raises hopes for upcoming EU approval. ... Belgian biotech TiGenix has racked up another positive result for its Takeda-partnered stem cell

  • Improving the prospects for ATMPs in Europe

    Schneider highlighted cell-based product, TiGenix' ChondroCelect for cartilage repair in the knee, which is a major success story for the ATMP sector as it remains the only cell-based product

More from news
Approximately 5 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel), an allogeneic stem cell therapy ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead

  • Deal Watch July 2016 Deal Watch July 2016

    Other deals where the licensee has committed real upfront money include Takeda's $28m upfront payment for ex-US rights to TiGenix's Cx601, a suspension of allogeneic adipose-derived stem ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment

  • Pharma deals in July 2015 Pharma deals in July 2015

    At the most extreme in terms of a low upfront is the $7m paid by Tigenix in the $293m acquisition of Coretherapix, presumably because stem cell therapies are high risk. ... Coretherapix / Tigenix. Company acquisition. Cardiac stem cell in Phase 2.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Bone Therapeutics strengthens board with new chairman Bone Therapeutics strengthens board with new chairman

    Bone Therapeutics strengthens board with new chairman. Jean Stéphenne joins the cell therapy company from TiGenix. ... Stéphenne’s career history has seen him serve in senior leadership roles at several biotechnology and pharmaceutical companies,

  • Belgium's TiGenix appoints Dr Gregory Gordon Belgium's TiGenix appoints Dr Gregory Gordon

    Belgium's TiGenix appoints Dr Gregory Gordon. He takes up a role as head of its US medical development. ... Meanwhile, Valles-Sukkar arrives at TiGenix from Alexion Pharmaceuticals, where she was responsible for all aspects of clinical trial development.

  • Eduardo Bravo becomes head of EBE Eduardo Bravo becomes head of EBE

    Eduardo Bravo becomes head of EBE. TiGenix CEO appointed president of the EBE’ s board of directors. ... He c urrently serves as chief executive officer of TiGenix, a biopharma company based in Belgium, and p rior to this served as Cellerix's chief

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    Belgium-based cell therapy company TiGenix has appointed Dr Marie Paule Richard as its new chief medical officer. ... We are very fortunate to have biopharma development, regulatory and commercialisation heavyweight Marie Paule joining the TiGenix

More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics